Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. Issue 3 (29th December 2021) - Delimpasi, Sosana; Mateos, Maria Victoria; Auner, Holger W.; Gavriatopoulou, Maria; Dimopoulos, Meletios A.; Quach, Hang; Pylypenko, Halyna; Hájek, Roman; Leleu, Xavier; Dolai, Tuphan Kanti; Sinha, Dinesh Kumar; Venner, Christopher P.; et al.